Therapeutic efficacy of 188Re-liposome in a C26 murine colon carcinoma solid tumor model
- First Online:
- Cite this article as:
- Chang, YJ., Hsu, CW., Chang, CH. et al. Invest New Drugs (2013) 31: 801. doi:10.1007/s10637-012-9906-7
- 374 Downloads
Nanoliposomes are good drug delivery systems that allow the encapsulation of drugs into vesicles for their delivery. The objective of this study is to investigate the therapeutic efficacy of a new radio-therapeutics of 188Re-labeled pegylated liposome in a C26 murine colon carcinoma solid tumor model. The safety of 188Re-liposome was evaluated before radiotherapy treatment. The anti-tumor effect of 188Re-liposome was assessed by tumor growth inhibition, survival ratio and ultrasound imaging. Apoptotic marker in tumor was also evaluated by the TUNEL (terminal deoxynucleotidyl transferase biotin-dUTP nick-end labeling) method after injection of 188Re-liposome. The group treated with 188Re-liposome displayed slight loss in body weight and decrease in white blood cell (WBC) count 7 to 14 days post-injection. With respect to therapeutic efficacy, the tumor-bearing mice treated with 188Re-liposome showed better mean tumor growth inhibition rate (MGI) and longer median survival time (MGI = 0.140; 80 day) than those treated with anti-cancer drug 5-FU (MGI = 0.195; 69 day) and untreated control mice (MGI = 0.413; 48 day). The ultrasound imaging showed a decrease in both tumor volume and number of blood vessels. There were significantly more apoptotic nuclei (TUNEL-positive) in 188Re-liposome-treated mice at 8 h after treatment than in control mice. These results evidenced the potential benefits achieved by oncological application of the radio-therapeutics 188Re-liposome for adjuvant cancer treatment.